Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women

Fertility and Sterility

Volumn 86, Issue SUPPL. 1, 2006, Pages

  Ibáñez, Lourdes ^a   de Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Body composition; hyperinsulinemia; hyperinsulinemic hyperandrogenism

Indexed keywords

CONTRACEPTIVE AGENT; ESTROPROGESTAGEN; FLUTAMIDE; METFORMIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANOVULATION; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EMBRYOTOXICITY; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERINSULINEMIC HYPERANDROGENISM; INFLAMMATION; INSULIN SENSITIVITY; LIVER TOXICITY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 33745190800     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.03.006     Document Type: Article

References (10)

1. Kirchengast S., and Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16 (2001) 1255-1260
2. Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., and Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome. a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
3. Orio Jr. F., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
4. Tarkun I., Arslan B.C., Canturk Z., Turemen E., Sahin T., and Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome. relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
5. Diamanti-Kandarakis E., Baillargeon J.P., Iuorno M.J., Jakubowicz D.J., and Nestler J.E. A modern medical quandary. polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88 (2003) 1927-1932
6. Ibáñez L., Valls C., Ferrer A., Ong K., Dunger D., and de Zegher F. Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 87 (2002) 2870-2874
7. Gambineri A., Pelusi C., Genghini S., Morselli-Labate A.M., Cacciari M., Pagotto U., and Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 60 (2004) 241-249
8. Ibáñez L., and de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and young women with hyperinsulinemic hyper-androgenism. opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89 (2004) 1592-1597
9. Ibáñez L., Valls C., and de Zegher F. Discontinuous flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinemic hyperandrogenism. normalizing effects on C-reactive protein, tumor necrosis factor-α and the neutrophil/lymphocyte ratio. Hum Reprod 21 (2006) 451-456
10. Ibáñez L., Jaramillo A., Ferrer A., and de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 20 (2005) 1833-1836